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Antidepressant Prescribing Practices for the Treatment of
Children and Adolescents
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Michael A. Sitorius, M.D.,1 Bruce A. Buehler, M.D.,1 and Christopher J. Kratochvil, M.D.1
ABSTRACT
Objective: This study evaluates pediatric antidepressant prescribing practices of Nebraska
clinicians.
Methods: Surveys were sent in July, 2005, to 1,521 prescribing clinicians throughout Ne-
braska to assess pediatric antidepressant use along with any practice changes following the
U.S. Food and Drug Administration (FDA) “black box” warning issued in October, 2004.
Results: Over half (n 5 866) of the clinicians responded to the survey, of which 96.8% re-
ported awareness of the FDA “black box” warning. Of the respondents, 76.9% (n 5 666) were
prescribing antidepressants to children and/or adolescents. Clinicians reported decreased pre-
scribing frequency for both children (15.5%) and adolescents (36.6%), with 36% having in-
creased referrals to specialists. While 31.9% reported seeing patients more frequently upon
initiation of antidepressants, only 7.5% reported weekly visits for the first month of treat-
ment, as recommended by the FDA. Over one fifth (21.9%) reported a caregiver or patient had
refused antidepressant medication treatment due to the FDA’s warning.
Conclusion: Clinicians in Nebraska report changes in clinical practice due to the issuance
of the FDA “black box” warning, with a decrease in prescribing antidepressants to pediatric
patients and an increase in referrals to specialists. Although awareness of the FDA’s warning
was evident among clinicians and patients, adherence to recommended guidelines was low.
INTRODUCTION
THERE HAS BEEN MUCH DEBATE over the linkbetween antidepressant use and suicidality
in the pediatric population (Whittington et al.
2004). The use of antidepressants to treat chil-
dren and adolescents with major depressive
disorder (MDD) had grown steadily in recent
years due, in part, to available efficacy data for
adults (Kratochvil et al. 2006). It was not until
1997, that evidence of antidepressant efficacy
in youths was documented with the first 
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randomized, placebo-controlled, double-blind
study showing the efficacy of fluoxetine in chil-
dren and adolescents (Emslie et al. 1997). It was
around this time that the U.S. Congress passed
the 1997 U.S. Food and Drug Administration
(FDA) Modernization Act. This Act provided
6-month patent extensions for pediatric stud-
ies, which prompted an increase in industry-
sponsored MDD studies in children and ado-
lescents. A vigorous response was evidenced
by the number of controlled pediatric depres-
sion studies conducted subsequently, followed
by the publication of several industry-funded
trials of fluoxetine, paroxetine, sertraline,
citalopram, and escitalopram (Emslie et al.
2002; Wagner et al. 2003; Wagner et al. 2004;
Emslie et al. 2006; Rynn et al. 2006; Wagner et
al. 2006; Bridge et al. 2007).
In 1998, on the basis of available data, the
American Academy of Child and Adolescent
Psychiatry (AACAP) published practice guide-
lines recommending selective serotonin reup-
take inhibitors (SSRIs) for the treatment of the
acute phase of MDD (Birmaher et al. 1998).
Around the same time, The Texas Children’s
Medication Algorithm Project also emphasized
the use of SSRIs for the treatment of pediatric
MDD (Hughes et al. 1999). An increase in pedi-
atric antidepressant use followed, as described
by Valuck and colleagues (2004), who reported
that the number of adolescents receiving an an-
tidepressant for a new episode of depression
grew from 5% in 1998 to 37% in 2002. As noted
by Vitiello and co-authors (2006), the total
number of adolescents receiving antidepres-
sants grew from 1.8% in 1999 to 4.0% in 2000.
Interestingly, the majority of the pediatric
depression trials have failed to demonstrate ef-
ficacy on their primary outcome measures. Flu-
oxetine is the only antidepressant to date that
has demonstrated efficacy in at least three pe-
diatric trials, involving 754 youths ages 8–18
years (Emslie et al. 1997; Emslie et al. 2002;
TADS Team 2004). Following review of data
from the first two trials, the FDA approved flu-
oxetine for the treatment of pediatric MDD in
January of 2003. Currently, fluoxetine remains
the only antidepressant approved for the treat-
ment of pediatric MDD.
Not long after the approval of fluoxetine by
the FDA, however, the Medicine and Health
Care Products Regulatory Agency (MHRA) of
the British Department of Health reported that
another SSRI, paroxetine, demonstrated a
slight increase in suicidal ideation and behav-
ior in children and adolescents with MDD
(Hammad et al. 2006). This notice was the first
of several issued by the MHRA, and subse-
quently the FDA, expressing concerns regard-
ing antidepressant use in youths, prompting
both regulatory agencies to review available
data with a goal of assessing the risk/benefit
relationship of these treatments in the pediatric
population (Kratochvil et al. 2006).
In 2004, the results of a meta-analysis in-
cluding 24 controlled clinical trials (approxi-
mately 4,400 pediatric patients) of nine antide-
pressants conducted for various indications
were presented at a public hearing in Wash-
ington D.C. Although there were no completed
suicides within any of the trials, the cumula-
tive risk of spontaneously reported suicidality
was 4% for active medication and 2% for
placebo (Hammad et al. 2006).
Following the hearing and on the basis of the
recommendations of the Psychopharmacologic
Advisory Committee and the Pediatric Sub-
committee of the Anti-Infective Drugs Advi-
sory Committee, the FDA issued a “black box”
warning for all antidepressants. The warning
stated that an increased risk of suicidality ac-
companies the use of an antidepressant in the
pediatric population for any indication (FDA
2004). Further FDA actions included manda-
tory distribution of a medication guide with
each antidepressant prescription filled for chil-
dren or adolescents, and the issuance of spe-
cific monitoring guidelines. The guidelines
stated that upon initiation of antidepressant
treatment the clinician should follow up with
weekly face-to-face visits for the first 4 weeks,
biweekly visits for the next 4 weeks, and then
continue with a monitoring visit 4 weeks later
(FDA 2005). The frequency of initial visits rec-
ommended in the FDA’s monitoring guidelines
are compatible with recent findings that indi-
cate the first 1–9 days after initiation of treat-
ment with an SSRI is the critical period for in-
creased risk of suicidal behavior (Jick et al.
2004; Simon et al. 2006, Simon et al. 2007).
Following the FDA’s Public Health Advisory
and subsequent warning, the number of anti-
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depressant prescriptions written for pediatric
patients decreased by about 20% (Rosack 2005;
Nemeroff et al. 2007). Recent data from Ten-
nessee show a similar trend, with a 33% de-
crease in new antidepressant users (Kurian et
al. 2007). Although causality cannot be as-
sessed, current Centers for Disease Control
(CDC) data indicate that the number of com-
pleted suicides in youth under the age of 20
increased between 2003 and 2004 by 18.2%
(Hamilton et al. 2007; Rosack 2007). Gibbons
and co-authors (2007) recently assessed data
from both the United States and the Nether-
lands, which show an increase in the rate of
child and adolescent suicide in the Nether-
lands to be 49% between 2003 and 2005, and
14% in the United States between 2003 and
2004. Their data also illustrate a concurrent de-
crease in the number of SSRI prescriptions to
be about 22% in both countries, which dem-
onstrates an inverse relationship between the
rate of completed suicides and the rate SSRI
prescriptions (Gibbons et al. 2007). In addi-
tion, recent data show that even the diagnosis
of pediatric depression has significantly devi-
ated from historical trends since the issuance
of the FDA warning and of those who are di-
agnosed, a large proportion are not receiving
antidepressant treatment (Libby et al. 2007).
With suicide as the third leading cause of
death among children and adolescents 10–19
years of age, it is important to consider the risk
of not treating MDD in the risk/benefit as-
sessment of antidepressant use in youth (An-
derson 2002; Hamilton et al. 2007). Addition-
ally, the warning seems to be shifting mental
health services from the primary care setting
to specialists (Nemeroff et al. 2007). This shift
may lead to increased demand on an already
stressed mental health system. These factors
highlight the importance of examining pedi-
atric antidepressant prescribing practices fol-
lowing the FDA’s directive, assessing both
changes in use of pharmacotherapy, as well as
changes in how the medications are monitored
in patients.
This study is a systematic review of practi-
tioner patterns of treatment and monitoring of
pediatric antidepressant use in Nebraska, with
the aim of determining the clinical implications
of the FDA warning in this state.
METHODS
In July of 2005, 9 months following the place-
ment of the “black box” warning, prescribing
clinicians throughout Nebraska completed a
self-administered mail-in survey. This survey
intended to capture the acute response of pre-
scribing clinicians to the black box warning and
address items including: provider frequency 
of prescribing antidepressants to children and
adolescents, comfort with prescribing antide-
pressants, monitoring and treatment practices,
referral patterns and wait time, medication
treatment refusal rates, and changes in clinical
practice subsequent to the warning. The study
was reviewed by the Institutional Review
Board at the University of Nebraska Medical
Center (UNMC), and determined to be an ex-
empt protocol.
Sample
A total of 1,521 prescribing clinicians in Ne-
braska received the opportunity to complete 
a survey regarding pediatric antidepressant
treatment and monitoring practices. Surveys
were distributed by mail in July and August of
2005. Participants included a variety of clini-
cians with prescribing authority thought to be
most likely to treat depressed children and ado-
lescents: all identified child and adolescent
psychiatrists, general psychiatrists, pediatri-
cians, family practice physicians, residents and
fellows training in these specialties, nurse prac-
titioners, and physician assistants throughout
the state.
Contact information for prescribing clini-
cians in Nebraska was obtained from the
Health Professionals Tracking Center (HPTC)
at UNMC. The HPTC collects information from
professional health-care providers throughout
the state by surveying hospitals, clinics, and
professionals throughout the year and by
means of collaboration with state licensure
boards. Some professionals not included in the
HPTC, such as those new to clinical practice in
Nebraska or those who had not submitted data
to the HPTC, were identified and added to the
database of prescribing clinicians through in-
formation provided by Nebraska Academy of
Family Physicians and a UNMC Department of
Psychiatry practitioner database. This pro-
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vided the most complete clinician database
available.
All identified clinicians received a letter ex-
plaining the purpose of the study along with a
survey. The letter informed participants that
the survey was assessing clinician prescribing
practices of antidepressants for the treatment
of depression in children and adolescents with
the goal of the study being to identify new chal-
lenges faced by clinicians treating depressed
children and adolescents since the issuance of
the FDA warning. The clinicians were asked to
complete the survey within 2 weeks and return
it in an enclosed postage-paid envelope. Track-
ing numbers were included on each survey, al-
lowing for a certain degree of anonymity but
also the opportunity to follow up with those
who had not completed the survey within 2
weeks of delivery. Clinicians who did not re-
spond to the initial survey received one addi-
tional letter reiterating the above information
and providing an additional copy of the sur-
vey. No further contact was made with clini-
cians beyond the second mailing. Once surveys
were returned the survey response data was
entered anonymously into a secure database.
Survey
Participating clinicians completed the Pedi-
atric Mental Health Resources and Antide-
pressant Prescribing Practices Survey, which
was designed by the study investigators specif-
ically for use in this assessment of prescribing
practices in Nebraska. The survey was pilot
tested with a small group of clinicians at
UNMC to assess readability, comprehension,
and clarity of the instrument.
The 13-item survey collected both demo-
graphic and clinical information, primarily by
means of closed-ended questions with varying
formats (categorical, numerical, multiple
choice, and Likert-scale). All items referenced
antidepressant use and practices for children
and adolescents only. The survey items are pre-
sented in Table 1.
Data analysis
Each survey returned was entered into a se-
cure database. Population sizes of the practice
locations reported were obtained from the Ne-
braska Department of Economic Development
(Nebraska Department of Economic Develop-
ment 2005). Surveys were then categorized
upon entry as exclusively urban or rural local-
ities using the Census Bureau classifications
from Census 2000 (U.S. Census Bureau 2005)
Descriptive statistics were used to evaluate
frequencies of the individual responses. Re-
sponses were analyzed by the clinicians’ spe-
cialty and locality (urban versus rural) as well,
where applicable. Frequencies and percentages
are provided to summarize categorical data,
whereas means and standard deviations are
provided to summarize continuous variables.
All statistical analyses were run using SPSS
version 13.0 for Windows (SPSS Inc. 2004).
RESULTS
Sample
A total of 866 surveys (57.5%) were returned
containing responses, with 20 surveys returned
as undeliverable. Respondent data are pre-
sented in Table 2. The surveys represent prac-
tices from 140 communities throughout the
State of Nebraska. Sixty-two respondents
(7.2%) reported practicing in multiple loca-
tions. Although practice settings were primar-
ily urban (85.3%), the surveys returned pro-
vided a diverse sample of population sizes.
Approximately one half (45.7%) of respondents
practiced in locations with populations
.100,000. However, 21.5% provided services in
areas with population sizes of 10,000–100,000,
with a significant number (32.7%) practicing in
areas of ,1,000 people.
Awareness and comfort level
Among the surveys returned (N 5 866),
nearly all (96.8%) of the respondents were
aware of the “black box” warning, which was
consistent across specialties [mean 95.0%, stan-
dard deviation (SD) 8.2%].
About half (49.2%) of the clinicians described
feeling “moderately comfortable” to “comfort-
able” in prescribing antidepressants to children
and adolescents. This comfort level was simi-
lar among urban (48.7%) and rural (51.9%) clin-
icians. Few respondents (8.3%) felt “very com-
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Type of clinician: (please check) Family medicine




What city/town is your clinic(s) located in? (please list) Physicians Assistant








Are you aware of the FDA black box warning issued for Yes/No
antidepressant use in the treatment of children and adolescents?
Before October 2004 (FDA black box warning issued for antidepressants) Yes/No
did you prescribe antidepressants to:
Children (,12 years old)
Adolescents (12–18 years old)
Do you currently prescribe antidepressants with the same frequency as Yes/No
prior to October 2004 to: If No: More/Less
Children (,12 years old)
Adolescents (12–18 years old)
How comfortable do you feel prescribing antidepressants to children 0 5 not comfortable to
and adolescents? (please circle) 5 5 very comfortable
Please identify the antidepressants you most frequently prescribe for Open-ended (requested top three)
treatment of children and adolescents, please list in order of frequency:
Upon initiation of treatment with antidepressants, how frequently is a 0,1,2,3,4 or .4
youth seen at your office in the 1st month of treatment (including the 
first visit when antidepressant is prescribed)?
How likely are you to refer children and/or adolescents to the following More, Same, Less (for each 
clinicians for mental health treatment since the issuance of the black selection)
box warning?
Child and adolescent psychiatrist Counselor
General psychiatrist Physicians assistant
Social worker Nurse practitioner
Psychologist Other: _________________________
What is the typical referral wait time for a psychiatrist or child 0–2 weeks
psychiatrist in your area: (please circle) 2–4 weeks
Current 4–6 weeks
1 year ago 6–8 weeks
.8 weeks
Have your treatment practices for children and/or adolescents treated Yes/No
with antidepressants changed since the FDA black box warning? If yes how:
More psychotherapy rather than 
medications
Refer more to specialists
More frequent visits
More frequent phone contacts
No longer treats with 
antidepressants
Have patients or guardians refused antidepressant medication treatment Yes/No
due to the FDA black box warning? If Yes, what percentage?
Parent/guardians _______
Patients _______
Note: Table items reflect verbatim the questions listed on the Pediatric Mental Health Resources and Antidepressant
Prescribing Practices Survey.
fortable” in prescribing antidepressants to chil-
dren and adolescents. Psychiatric clinicians
were most likely to report being “very com-
fortable” (27.2%), followed by pediatric clini-
cians (8.3%) and family medicine clinicians
(5.1%). Approximately one in five (21.9%) of re-
spondents reported experiencing caregivers or
patients refusing antidepressant medication
treatment due to the FDA “black box” warn-
ing. Those clinicians experiencing refusals, re-
port averages of 20.1% ( SD 19.2%) of caregivers
and 9.1% (SD 15.1%) of patients refusing treat-
ment with an antidepressant, suggesting that
parent and youth comfort level was influenced
by the warning as well.
Treatment changes
The majority (76.9%, n 5 666) of responding
clinicians were prescribing antidepressants to
children and/or adolescents prior to the FDA
warning. Of the 666 clinicians who were pre-
scribing to children and/or adolescents prior
to the warning, 39.2% were prescribing antide-
pressants to children (,12 years old) and 99.5%
were prescribing to adolescents. Clinicians
were prescribing at a lessened frequency fol-
lowing the warning, with 15.5% reporting a de-
crease in prescribing antidepressants to chil-
dren and 36.6% reporting a decrease in pre-
scribing to adolescents.
Of the total responding clinicians (N 5 866),
a few clinicians (4.7%) report no longer treat-
ing the children or adolescent patients in their
care with antidepressants. Pediatric clinicians
reported the largest rate of discontinuation 
of prescribing antidepressants (11.5%), with
fewer family medicine (3.9%) and psychiatric
(0.8%) clinicians reporting completely ceasing
treatment with antidepressants.
Modifications in monitoring practices were
also reported, with 31.9% reporting more fre-
quent patient contacts upon initiation of treat-
ment with antidepressants. Respondents re-
ported an average of 2.15 (SD 0.82) office
contacts (including the initial visit) within the
first month of treatment. Interestingly, how-
ever, only 7.5% of clinicians responded that
they were seeing patients weekly for the first
month as recommended by the FDA.
Over one third (36.0%), of the responding
clinicians described increased referrals to spe-
cialists, with 54.5% increasing their referrals to
psychiatrists and 39.6% increasing referrals to
psychologists, social workers, or counselors.
This increase in referrals may be related to the
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TABLE 2. PRESCRIBING PRACTICES BEFORE AND AFTER FDA WARNING (N 5 866)
Prescribe antidepressants Prescribe antidepressants
Percent of to children and adolescents to children and adolescents
Specialty (N) sample prior to FDA warning (n) after FDA warning (n)
Family medicine clinicians (605) 69.9% 79.8% (483) 68.3% (413)
Family medicine (363)
Family medicine nurse practitioner (69)
Family medicine physician assistant (141)
Family medicine resident (25)
General practice (7)
Pediatric clinicians (139) 16.0% 69.1% (96) 65.5% (91)
Pediatrician (114)
Pediatric nurse practitioner (10)
Pediatric physician assistant (12)
Developmental and behavioral (3)
Psychiatric clinicians (122) 14.1% 71.3% (87) 71.3% (87)
General psychiatrist (65)
Child and adolescent psychiatrist (20)
Psychiatric nurse practitioner (17)
Psychiatric physician assistant (6)
Psychiatric resident (14)
Urban rural (N)
Urban (739) 85.3% 75.5% (558) 68.1% (503)
Rural (127) 14.7% 85.0% (108) 68.3% (88)
change in perceived psychiatric referral wait
times following the warning. The majority of
clinicians (52.1%), both urban (23.8%) and rural
(28.3%), perceived that there was an increase in
referral wait times by at least 2–4 weeks fol-
lowing the issuance of the warning. Unexpect-
edly, urban and rural clinicians reported simi-
lar wait times across the visit intervals. Further
details of practice changes are presented in Fig.
1 and Table 3.
When selecting an antidepressant, clinicians
typically preferred prescribing SSRIs for the
treatment of children and adolescents. The
most frequently prescribed antidepressants are
presented in Table 4.
DISCUSSION
The aim of this study was to evaluate anti-
depressant prescribing practices for children
and adolescents 9 months after the issuance of
the FDA “black box” warning. Prescribing clin-
icians throughout the State of Nebraska were
surveyed. The clinicians who responded rep-
resent the diversity of treatment providers
throughout the state in specialty, location, and
community population size. When comparing
the results of this study to national data, Ne-
braska has a similar pattern of physician dis-
tribution as compared to many other states
with regard to specialty types and practice lo-
cation (urban versus rural) (American Medical
Association 2007).
Awareness of the FDA’s warning was high
across specialties and regions, with many clin-
icians indicating changes in prescribing and
monitoring practices due to the “black box”
warning. As expected, since the issuance, there
has been a decrease reported by clinicians in
the use of antidepressants among children and
















































TABLE 3. PSYCHIATRIC REFERRAL WAIT TIMES (N 5 866)
Referral wait time (weeks)
Not answered 0–2 2–4 4–6 6–8 .8
At the time of survey
Urban (n 5 739) 13.7% 9.5% 21.5% 23.8% 15.6% 15.9%
Rural (n 5 127) 6.3% 11.0% 23.6% 28.3% 13.5% 17.3%
Prior to FDA warning
Urban (n 5 739) 20.6% 8.4% 22.2% 20.7% 14.3% 13.8%
Rural (n 5 127) 10.2% 10.2% 26.9% 24.4% 11.0% 17.3%
FIG. 1. Treatment changes following the FDA’s black box warning (N 5 866).
a fair number of clinicians prescribed at a lesser
rate, relatively few stopped using antidepres-
sants in children and adolescents altogether.
The decrease in the number of clinicians pre-
scribing to children and adolescents is consis-
tent with the national decrease in the rate of
prescriptions since the issuance of the warning
(Rosack 2005; Nemeroff et al. 2007).
In addition to lowered prescribing frequen-
cies, clinicians reported practice changes as
well. The most common practice modifications
were increased referrals to specialists and in-
creased visit frequency, although less than 1 in
10 met the FDA recommended guideline for
weekly face-to-face visits during the first
month of treatment with an antidepressant.
Although few clinicians report the use of
psychotherapy in lieu of medications, a num-
ber report increasing referrals to psychologists,
social workers, and counselors. This may indi-
cate that some clinicians are using psychother-
apy as an adjunct to pharmacotherapy, or pos-
sibly as a means of increasing visit frequency
and safety monitoring when they initiate treat-
ment with antidepressants. This combination
of treatments may ease the burden on the pre-
scribing clinician and provide for greater in-
tensity of services, while concurrently provid-
ing some level of increased safety monitoring
when initiating antidepressant treatment in
youth. The Treatment for Adolescents with De-
pression Study (TADS) demonstrated that the
combination of cognitive behavioral therapy
and fluoxetine offered the most favorable
tradeoff between benefit and risk for adoles-
cents with MDD (TADS Team 2004). This treat-
ment plan may not be feasible for all patients
however, as obstacles such as location (avail-
ability of psychologists, social workers, or
counselors in the area), mental health insurance
coverage, and personal schedules may make
weekly psychotherapy sessions difficult.
Prospective studies are needed to address the
impact of the “black box” warning on patient
concerns regarding antidepressant use, actual
changes in monitoring practices, changes in
clinical care, and impact on clinical outcomes.
On the basis of this retrospective study, the
“black box” warning appears to have presented
new challenges in providing mental health
care. Although clinicians in Nebraska were in-
creasing the frequency of visits, they were not
seeing patients weekly during the first month
of treatment as initially recommended by the
FDA. It is unclear what liability this potentially
posed for clinicians who did not specifically
follow the FDA guidance, and what impact this
could have had longitudinally for care in a state
with limited mental health resources. It is of
note that in May, 2007, the FDA proposed that
the antidepressants’ package inserts be ex-
panded to include an increased risk of suici-
dality in young adults ages 18–24 (FDA 2007).
The new revisions to the package insert now
cease to provide monitoring guidelines (FDA
2007). Additionally, they include new language
in the warning that state depression or other
psychiatric illnesses themselves may be a risk
for suicide (FDA 2007).
Interestingly, the survey showed that practi-
tioners in this state were frequently prescribing
medications that are not FDA approved for use
in children and adolescents with MDD. Al-
though other SSRIs have some support in the
literature for the treatment of pediatric depres-
sion, only fluoxetine is FDA approved for this
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TABLE 4. MOST FREQUENTLY PRESCRIBED ANTIDEPRESSANTS
More common antidepressant choice
1st Choice 2nd Choice 3rd Choice
Clinicians prescribing antidepressants Sertraline (39.8%) Fluoxetine (19.4%) Escitalopram (18.5%)
to children and adolescents (N 5 866)
By specialty
Family medicine (n 5 605) Sertraline (35.0%) Escitalopram (14.1%) Fluoxetine (13.4%)
Pediatric (n 5 139) Sertraline (24.5%) Fluoxetine (15.1%) Escitalopram (10.1%)
Psychiatric (n 5 122) Fluoxetine (22.1%) Escitalopram (19.7%) Sertraline (15.6%)
use in this population. It is of note that whereas
fluoxetine was the first choice among the psy-
chiatric clinician respondents, for family med-
icine and pediatric clinicians it was the second
and third most common “first choice,” respec-
tively. This finding indicates that factors other
than the official label of medication influence
prescribing practices in the treatment of men-
tal conditions in children and adolescents.
Effects on comfort level were evident, with
only slightly more than half of clinicians re-
porting that they were comfortable prescribing
antidepressants to children and adolescents.
Not surprisingly, psychiatric practitioners
were the clinicians who felt the most comfort-
able with prescribing antidepressants to chil-
dren and adolescents and were the least likely
to change their prescribing practices after the
warning. Patient comfort level appears to have
been affected as well, as a fair number of clin-
icians report that patients have refused antide-
pressant medication treatment due to the
FDA’s warning. Continued education for the
clinician as well as the patient is important, and
may aid in increasing comfort levels for both.
Additionally, continued education is important
to enhance the competency of the clinicians
providing care to depressed pediatric patients.
These data indicate that the large majority of
clinicians were not following the recommen-
dations set forth by the FDA, but not simply
due to an unawareness of the “black box”
warning. The findings also indicate that there
were concerns, potentially justified, with using
these medications. By providing educational
opportunities to the general medical commu-
nity, the hope would be that more clinicians are
able to provide appropriate and effective men-
tal health care to children and adolescents. This
may help decrease the strain caused by too few
child and adolescent psychiatrists available in
the community, and increase access to appro-
priate care. Further research is needed to assess
the degree to which sufficient resources are
available regionally to treat children and ado-
lescents with mental health issues.
Limitations
Customary mail-in surveys limitations were
expected and evident in this study. The survey
format does not allow for clarification of an-
swers or questions and respondents are unable
to add explanations or additional information.
We were unable to compare the demographics
of responders and nonresponders due to the
anonymity of the survey and of the available
clinician database. Additionally, while we were
able to sample a diverse group of providers in
various community sizes, we only surveyed
clinicians in the State of Nebraska; thus, it is
possible that the results are relevant only to Ne-
braska clinicians. Although we have an ample
sample size that is fairly representative across
specialties, regions, and population sizes, it re-
mains possible that those completing the sur-
vey are a biased group, perhaps those that are
most comfortable with treating pediatric MDD.
CONCLUSION
The FDA warning and the concerns regard-
ing antidepressant use in youths have pre-
sented the mental health community with new
challenges in an already stressed health-care
system. Scheduling more frequent follow up,
increasing use of psychotherapy, and adding
telephone contacts between visits may help to
provide patients with an improved level of
monitoring during treatment with an antide-
pressant. The most recent FDA changes are
quite noteworthy in that they also recognize
that there is an inherent risk in having a men-
tal illness itself, which may urge clinicians to
re-evaluate the risk/benefit relationship of pre-
scribing antidepressants to youths. In light of
the recent changes, patient and parent educa-
tion remains essential to facilitate adherence,
safety, as well as in helping youths and parents
understand the importance of working to-
gether with the clinician as a team in the treat-
ment of MDD. 
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